Trials / Not Yet Recruiting
Not Yet RecruitingNCT06416930
Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (estimated)
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, single-arm, phase II clinical study to evaluate the safety and efficacy of Cadonilimab combined with gemcitabine, or vinorelbine, or pemetrexed in the treatment of patients with recurrent / refractory pleural mesothelioma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cadonilimab Combined with chemotherapy | Cadonilimab (15mg/kg, intravenous drip, D1) + gemcitabine (1250mg/m2, intravenous drip, D1/D8) or vinorelbine (30mg, oral, tiw, D1/D3/D5) or pemetrexed (500mg/m2, intravenous drip, D1), every 3 weeks. |
Timeline
- Start date
- 2024-06-20
- Primary completion
- 2027-06-20
- Completion
- 2029-06-20
- First posted
- 2024-05-16
- Last updated
- 2024-05-16
Source: ClinicalTrials.gov record NCT06416930. Inclusion in this directory is not an endorsement.